Binimetinib is an oral, highly selective MEK1/2 inhibitor used in combination with encorafenib for BRAF V600E/K-mutated unresectable or metastatic melanoma and non-small cell lung cancer.
Products > Drug Discovery > Impurities > Anti-Neoplastic > Binimetinib and Impurities | Products > Drug Discovery > Inhibitor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye